Tag Archives: Takeda Pharmaceutical

October, 2018

24 October
Enterome and Takeda Enter Licensing, Co-Development and Co-Promotion Agreement for Crohn’s Disease Treatment

ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, …
Share
19 October
Takeda to Present Results from Phase 3 Trial Highlighting Intracranial Efficacy of Alunbrig Versus Crizotinib in First-Line Advanced ALK+ NSCLC

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma …
Share

25 September
Takeda to Present Positive Data from Alunbrig Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50% Versus Crizotinib in Advanced ALK+ NSCLC

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee …
Share

1 May
Takeda’s Alunbrig Receives Accelerated Approval for Treatment of ALK+ Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are …
Share

2 September
Takeda to Develop Zika Vaccine with up to $312 Million in Funding from US Government

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that BARDA, the Biomedical Advanced Research and Development Authority, has selected Takeda’s Vaccine Business Unit to develop a vaccine to support the Zika response in the US and affected regions around the world. Initial funding from BARDA, which is …
Share

8 February
Takeda Expands its ADC Collaboration with Mersana

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Mersana Therapeutics and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide …
Share